問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Chang Gung Medical Foundation (在職)

Division of Ophthalmology

Linkou Chang Gung Medical Foundation (在職)

Division of Ophthalmology

更新時間：2023-09-19

陳怡杏
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

5Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳怡杏

List

9Cases

2025-03-01 - 2032-01-31

Phase III

Active
A phase 3, open-label, multicenter, randomized trial comparing trastuzumab deruxtecan plus bevacizumab versus bevacizumab alone as first-line maintenance therapy for HER2-positive ovarian cancer (DESTINY-Ovarian01/ENGOT-ov89/GEICO144-O/GOG-3112/APGOT-OV13).

  • Condition/Disease

    Compare the efficacy of T-DXd plus bevacizumab (Group A) versus bevacizumab monotherapy (Group B) in the HER2 IHC 3+/2+ population, as assessed by BICR for progression-free survival (PFS).

  • Test Drug

    Trastuzumab Deruxtecan (T-DXd、DS-8201a)

Participate Sites
7Sites

Recruiting7Sites

2025-03-01 - 2026-12-31

Phase I

Active
An open-label, multicenter, platform study evaluating the safety, tolerability, bioactivity, and pharmacokinetics of various intravitreal injection therapies in retinal diseases—APEX

  • Condition/Disease

    It is used to treat inflammatory secondary macular edema (MESI) and is being explored as a treatment option for other retinal vascular diseases such as diabetic macular edema (DME).

  • Test Drug

    KSI-101

Participate Sites
3Sites

Recruiting3Sites

2023-01-01 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-08-01 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2020-08-01 - 2023-08-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
19Sites

Not yet recruiting8Sites

Recruiting1Sites

Terminated9Sites

2023-04-22 - 2026-10-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

2025-11-01 - 2028-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting4Sites

2024-02-01 - 2026-06-30

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-12-01 - 2028-02-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB